← Eichor
Study identifier: NCT07327359 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

Condition: Androgenetic Alopecia (AGA)  ·  Sponsor: Olix Pharmaceuticals, Inc.

PhasePhase 1/Phase 2
Planned participants158
Who can joinMale, 18 Years to 59 Years
Healthy volunteersYes

About this study

This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.

This description comes directly from the study's public registry record.

Talk to the study team

Emeritus Research Chief Executive officer  ·  +613 9509 6166  ·  info@emeritusresearch.com

Always discuss trial participation with your own doctor first.

Locations (1)

Emeritus Research CamberwellCamberwell, Victoria, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07327359